GRI Bio Inc News - GRI

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Live webcast on Wednesday, May 1st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio...

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications...

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary...

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

Live webcast on Wednesday, April 3rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio...

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and...

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the...

GRI Bio Announces Pricing of $5.5 Million Public Offering

LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...

GRI Bio Announces Reverse Stock Split

GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA...

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments...

GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on...

GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year...

GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases

Data presented at the 7th Annual Antifibrotic Drug Development (AFDD) Summit Company’s lead program, GRI-0621...

GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference

Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

GRI Bio Inc (GRI)

Professional-Grade Tools, for Individual Investors.

GRI News

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

GRI Bio Announces Pricing of $5.5 Million Public Offering

GRI Bio Announces Reverse Stock Split

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases

GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference

GRI Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

GRI Bio Inc (GRI) News

GRI Bio Inc (GRI)

Professional-Grade Tools, for Individual Investors.

GRI News

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

GRI Bio Announces Pricing of $5.5 Million Public Offering

GRI Bio Announces Reverse Stock Split

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases

GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference

GRI Discussion

Your Recent History